Prognostic role of early 18-FDG PET/CT during neoadjuvant chemotherapy for resectable adenocarcinoma of the esophagus and esophagogastric junction

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023884%3A_____%2F21%3A00008773" target="_blank" >RIV/00023884:_____/21:00008773 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11110/21:10419994 RIV/00064203:_____/21:10419994 RIV/00064165:_____/21:10419994

Result on the web

<a href="https://pubmed.ncbi.nlm.nih.gov/33440988/" target="_blank" >https://pubmed.ncbi.nlm.nih.gov/33440988/</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.4149/neo_2020_200815N863" target="_blank" >10.4149/neo_2020_200815N863</a>

Result language

angličtina

Original language name

Prognostic role of early 18-FDG PET/CT during neoadjuvant chemotherapy for resectable adenocarcinoma of the esophagus and esophagogastric junction

Original language description

We prospectively investigated whether metabolic response assessed by 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography (PET/CT) early in the course of neoadjuvant chemotherapy is predictive of survival in patients with adenocarcinoma of the esophagus and esophagogastric junction. PET/CT was performed before and in the third week after the initiation of the first cycle of neoadjuvant chemotherapy, which consisted of epirubicin, cisplatin, and 5-fluorouracil or capecitabine. The metabolic response was defined as a relative decrease in the peak standardized uptake value (SUL) of the tumor by ≥35% or total lesion glycolysis (TLG) by ≥66%. The associations of metabolic response with overall survival (OS) and disease-free survival (DFS) were investigated using Kaplan-Meier curves and multivariable Cox regression analysis. Among 126 recruited patients, the early metabolic response was assessed in 107 patients (90 of them underwent surgical resection). The five-year OS and DFS rates of all patients were 28% and 27%, respectively. No difference was found in OS (p=0.10 for SUL, p=0.08 for TLG) or DFS (p=0.50 for SUL, p=0.20 for TLG) between metabolic responders and non-responders. Post hoc analysis of the patients with a follow-up PET/CT within 16 days showed that metabolic response reflected by SUL predicted OS (p=0.03). We concluded that metabolic response assessed by PET/CT after the first cycle of neoadjuvant chemotherapy does not predict survival in patients with adenocarcinoma of the esophagus and esophagogastric junction. However, proper timing of the follow-up PET/CT may affect the prognostic ability of the early metabolic response.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

<a href="/en/project/NT12331" target="_blank" >NT12331: Early assessment of effectivness of neoadjuvant chemotherapy for carcinoma of the esophagus and esophago-gastric junction using FDG-PET/CT.</a><br>

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2021

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Neoplasma

ISSN

0028-2685

e-ISSN

—

Volume of the periodical

68

Issue of the periodical within the volume

2

Country of publishing house

SK - SLOVAKIA

Number of pages

11

Pages from-to

423-433

UT code for WoS article

000662127400020

EID of the result in the Scopus database

2-s2.0-85103919947